Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3393)	12/22/1997 7:29:00 PM
From: Izzy	Respond to of 6136

John, thanks. FWIW, Univ Calif Irvine College of Medicine and Dep't of Information and Computer Science have developed a computer program that evaluates a patient's HIV RNA gene sequence, determines drug-resistant mutations, and then lists the most effective treatment drug regimens for that specific patient---"Our goal is to eliminate the medical guesswork inherent in treating HIV-infected patients." Apparently this program is going to be made available commercially (? date). Contact is Dr. Michael Pazzani (pazzani@super-pan.ics.uci.edu). Unfortunately, I have been unable to obtain any further info so far, but this program most likely would be a tremndous asset to those doctors treating HIV patients. That is, each patient will receive an individualized treatment combo regimen consisting of known, effective drugs (including Viracept, of course).